Hand sanitizer and surface cleaner company Byotrol had a strong 2020 and are confident about 2021 Watch Now
The worlds biggest consumer of coal, China has announced they will be carbon neutral by 2060. They won't achieve that by burning coal and they won't want to just decommission their coal power plants as it costs too much and they still need the power. South Korean finance company already providing SAE with an 'in' in Asia. I could see SAE inking numerous global agreements over the coming years to convert power plants or provide feedstock. Either way thr market is immense and if proved at Uskmouth are the only player in that market and would be on track to dominate it.
I think they understand that getting this over the line and being able to keep all the profit means that they have a large, sustainable revenue platform for years to come which will allow them finance other projects without the need to raise through placings or debt. It is what will propel their business model forward by a considerable amount because of that guaranteed capital going forward. It opens up the possibilities of being able to close out numerous smaller projects quickly, generating more income and eventually projects like Deeside which is of a similar magnitude to Billingham and would generate considerable income. As I've said before, it's a snowball effect and. Billingham is crucial to giving the market confidence in their ability to close out a big project.
The RNS makes it sound like the only reason it is being extended is to iron out the buyout of the SPV prior to financial close. As if it's all ready to go but Eqtec wants 100% of the profits gained from the project so won't close until they have agreed with Scott Bros. Hmm.
To my mind if it wasn't a goer they'd know by now and would have announced the extension. The last 2 extensions have been announced weeks ahead of the deadline date because they knew it wouldn't be closed. If it gets extended last minute I will probably de risk slightly but still expect the SP to move up significantly over the LT. A firm hold for now and if Billingham lands then hold on to your hats!
He then corrected himself and said "some way off." But prior to both those statements he said that they were "on the brink" with LFT pregnancy style tests. Come on, don't misrepresent his words to suit your agenda.
I think they are likely doing that as part of the validation as there's a lot of talk from govt, AS and the scientific community of being able to identify people when they are infectious only and not picking up miniscule virus particles when someone isn't actually infectious. That's the main reason I'm not invested here and not in PCR companies because there will be a paradigm shift away from PCR (in my opinion).
Retireby40, I think you're slightly confused. It's higher sensitivity that picks up positive people who aren't infectious anymore. And the expectation is that sensitivity will not be over 95% (and that's at the high end), so only infectious people will test positive. Specificity is what is likely to be high (98/99%) which is all about ensuring you don't pick up false positives.
Some of you guys just need to chill. Boris has reconfirmed again their stated aim is for '"pregnancy style lateral flow tests". The science isn't there yet but we're "on the brink." Yes there's been some delays and yes there may be some competition but ultimately the market is HUGE. Football stadia alone counts for 10 million tests a month in ONE COUNTRY. Mass vaccination isn't going to happen for at least 6 months to a year, but possibly longer. We know Affirmers work and we know that there is no other LFT saliva test that's any good that's passed regulators and even if there was could they cater for the whole world? No. If you're not happy with the delay and think Avacta will be pipped to the post by others and make no money then sell up. Simple. It'll fly through validation and will be rolled out when it's ready. My guess is it'll be available in November looking at realistic timelines.
It wouldn't surprise me if they add it as a function to the test and trace app because that is also due soon. Self reporting isn't ideal and some people just won't do it. But most people who know they're infected will at least self isolate. I think govt will take the risk and put some of the responsibility on the public like they have with masks and social distancing in general. If the test works as advertised govt will buy as many as they can make initially then once production is ramped to a certain level the tests will be sold direct to the consumer through Medusa 19. There will almost certainly be a new manufacturing partner or 2 in the coming weeks (if it works), then the sky's the limit. Any vaccine won't make a dent in testing needs for at least a year but by then we'll hopefully have tons of cash in the bank and a successful cancer therapy. It's all good people, chill.
I've topped up with 10k new shares on the US govt buying up all Abbott's tests. The market is massive and even with competitors eating some of the market share Avacta still stands to benefit hugely (if the test works and they don't delay too much).
UK government policy is to test 4 million people a day by the NY. PCR testing currently accounts for approx 150k tests a day and require a massive organised operation including healthcare professionals and labs. Its reasonable to assume they couldn't scale up to more than a million tests a day for PCR. That leaves 3 million tests a day which will likely be completed using LFT anti gen tests. Even assuming that other LFT anti gen test providers take up 2 of that remaining 3 million a day, that leaves Avacta providing 1 million tests a day. BBI have said that they will be able to produce 'millions' of a tests a month at the start, which suggests capacity of less than 10 million a month to begin with, but if the test works then additional manufacturers will be found to scale up by NY. All in all it's reasonable to assume that UK govt alone will be buying 30 million tests a month from Avacta come the NY. Avacta quoted a retail price of $30 a few months back, but even assuming a lower price it's also reasonable to assume a profit per unit of $2-4. That's $60 million profit a month and $720 million profit a year. And these are low estimates, because if the test works as advertised and they can get additional manufacturers on board to produce say, 100 million tests a month, they will all sell and it will make them a $200 million a month and $2.4 billion over 12 months. I think on announcement the test works as advertised we will see a rise to £3. On news of orders it will hit £4 or £5. On news of a large scale up in manufacturing and pre-orders it will head up towards £10. If the cancer therapies work next year then we're looking at a SP above £10. After that the sky's the limit.
Bang on Phantom. AW, you know as well as I we do a company doesn't have to make profit equal to the value of its MCAP to justify that MCAP. Prime example at the moment - Tesla.
Looks like Palumbo has come through for us! This should be the catalyst for more contracts signed, more projects in the pipeline and a serious re rate! Slightly gutted I sold a 1/4 of my goldings last week when no news came for Greece but hey, you can't win them all.